| abstract |
A pharmaceutical dosage form having a first and a second active drug, said dosage form comprising: (a) a controlled release core of an antihyperglycemic drug and at least one pharmaceutically acceptable excipient; and (b) a component containing an immediate-release thiazolidinedione derivative comprising a thiazolidinedione derivative and a low viscosity water soluble binder having a viscosity of between 2 and 6 mPa · 10 s when tested as an aqueous solution at 2 % at 20 ° C, and said low viscosity water soluble binder is hydroxypropyl cellulose; wherein said controlled release core is an osmotic tablet and said thiazolidinedione derivative is applied as a layer to the controlled release core; and where no less than 90% of thiazolidinedione is released from the dosage form within 30 minutes when tested according to the United States Pharmacopeia (USP) 26, with Apparatus 1 at 100 rpm, 37 ° C and 900 ml of 0.3 M KCl-HCl buffer, pH 2.0. |